Descripción

Laboratory parameters including inflammatory markers in children with IBD receiving sodium butyrate or placebo supplementation alongside standard therapy are compared.

Figure 3

Chart

Source Paper

Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed Inflammatory Bowel Diseases-Randomized Placebo-Controlled Multicenter Trial.

Nutrients (2022)

PMID: 36014789

DOI: 10.3390/nu14163283

Cite This Figure

![Figure 3: Laboratory parameters including inflammatory markers in children with IBD receiving sodium butyrate or placebo supplementation alongside standard therapy are compared.]()

> Source: Anna Pietrzak et al. "Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed I." *Nutrients*, 2022. PMID: [36014789](https://pubmed.ncbi.nlm.nih.gov/36014789/)

<figure>
  <img src="" alt="Laboratory parameters including inflammatory markers in children with IBD receiving sodium butyrate or placebo supplementation alongside standard therapy are compared." />
  <figcaption>Figure 3. Laboratory parameters including inflammatory markers in children with IBD receiving sodium butyrate or placebo supplementation alongside standard therapy are compared.<br>  Source: Anna Pietrzak et al. "Sodium Butyrate Effectiveness in Children and Adolescents with Newly Diagnosed I." <em>Nutrients</em>, 2022. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/36014789/">36014789</a></figcaption>
</figure>

Evidencia relacionada

Butyrate (Sodium/Calcium Butyrate) para Ulcerative Colitis (UC)

Calificación C · 3 estudios

Butyrate (Sodium/Calcium Butyrate) para Crohn's Disease

Calificación C · 2 estudios